← Back to Clinical Trials
Recruiting NCT07367880

NCT07367880 The Monument Test : A New Tool for Assessing the Ability to Name and Identify Unique Entities. (TeDIMO)

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07367880
Status Recruiting
Phase
Sponsor University Hospital, Grenoble
Condition Alzheimer s Disease
Study Type OBSERVATIONAL
Enrollment 220 participants
Start Date 2026-02-23
Primary Completion 2031-02-01

Eligibility & Interventions

Sex All sexes
Min Age 50 Years
Max Age 95 Years
Study Type OBSERVATIONAL
Interventions
Identification and naming task

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 220 participants in total. It began in 2026-02-23 with a primary completion date of 2031-02-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of this study is to show a significant difference in performance between 2 groups of participants (healthy elderly people vs. people with Alzheimer Disease) in an identification and naming task involving famous monuments.

Eligibility Criteria

Inclusion criteria : * Alzheimer's disease: * Age ≥ 50 years and older * Possible or probable diagnosis of Alzheimer's disease according to the revised criteria of Mac Khann et al., 2011. * Score 18≤ MMSE ≤26 * Controls: * Age ≥ 50 years and older * MMSE score ≥ 26 For all subjects * No objection from the participant Exclusion criteria * Alzheimer's disease: * Persons referred to in Articles L1121-5 to L1121-8 of the CSP * Controls: * Memory complaints * Persons referred to in Articles L1121-5 to L1121-8 of the CSP For all subjects * Significant neurological or psychiatric history * Taking psychotropic medication (neuroleptics) * Poor command of the French language, comprehension difficulties * Significant hearing or visual impairments (diplopia, nystagmus, scotoma, etc.) * Insufficient exposure to the media and/or socio-cultural knowledge (questionnaire) ; Deficit in face recognition (Benton Face Recognition Test)

Contact & Investigator

Central Contact

Sabrina Iannuzzi, Neuropsychologist

✉ siannuzzi@chu-grenoble.fr

📞 +334.76.76.57.90

Frequently Asked Questions

Who can join the NCT07367880 clinical trial?

This trial is open to participants of all sexes, aged 50 Years or older, up to 95 Years, studying Alzheimer s Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07367880 currently recruiting?

Yes, NCT07367880 is actively recruiting participants. Contact the research team at siannuzzi@chu-grenoble.fr for enrollment information.

Where is the NCT07367880 trial being conducted?

This trial is being conducted at Grenoble, France.

Who is sponsoring the NCT07367880 clinical trial?

NCT07367880 is sponsored by University Hospital, Grenoble. The trial plans to enroll 220 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology